‌

Margetuximab Expanded Access Program

Overview Structured Data Issues Contributors

clinicaltrials.gov/study/NCT03133988

Is a

‌

Clinical study

Clinical Study attributes

NCT Number

NCT031339880

Trial Sponsor

MacroGenics

Official Name

An Expanded Access Program Providing Margetuximab in the Treatment of HER2+ Metastatic Breast Cancer in Single, Individually-approved Patients0

Last Updated

February 22, 2022

Study summary

The purpose of the Expanded Access program is to provide margetuximab to patients with pretreated HER2+ breast cancer for whom potential benefit justifies potential treatment risks.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like Margetuximab Expanded Access Program

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API